Cogent Biosciences (COGT) Receivables - Doubtful (2017 - 2023)

Cogent Biosciences (COGT) has 7 years of Receivables - Doubtful data on file, last reported at $157.1 million in Q4 2023.

• On a quarterly basis, Receivables - Doubtful rose 75.41% year-over-year to $157.1 million in Q4 2023; TTM through Dec 2023 was $157.1 million, a 75.41% increase from a year earlier, with the FY2023 full-year figure at $157.1 million, up 75.41% from the prior year.
• Receivables - Doubtful for Q4 2023 stood at $157.1 million, up from $89.5 million in the prior quarter.
• Over the last five years, Receivables - Doubtful for COGT reached as high as $157.1 million in Q4 2023 and fell as low as $27.8 million in Q4 2020.
• Historically, Receivables - Doubtful has averaged $71.9 million across 5 years, with a median of $46.7 million in 2021.
• Across the five-year window, Receivables - Doubtful retreated 27.77% in 2020 and soared 91.8% in 2022, its largest moves.
• Year by year, Receivables - Doubtful stood at $38.5 million in 2019, then slipped by 27.77% to $27.8 million in 2020, then surged by 67.94% to $46.7 million in 2021, then jumped by 91.8% to $89.5 million in 2022, then jumped by 75.41% to $157.1 million in 2023.
• Per Business Quant data, the three most recent Receivables - Doubtful figures were $157.1 million in Q4 2023, $89.5 million in Q4 2022, and $46.7 million in Q4 2021.